John B. Bode - 03 May 2023 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: Director
Issuer ticker: ZVRA
Reported as of: 03 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 May 2023, 21:44:43 UTC
Prior SEC filing: 08 May 2023
Next SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for John B. Bode

Key filing fact

John B. Bode filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 08 May 2023.

Key facts

This page summarizes John B. Bode's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 08 May 2023, 21:44.

Change

Previous filing in this sequence was filed on 08 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +58,800
Change %
Price: $0.000000
Shares after: 58,800
Date: 03 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 58,800
Exercise price: $4.97
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 3, 2023.

Footnote F2

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's ninth amended and restated non-employee director compensation policy.

Footnote F3

33.33% of the total shares subject to the option vest in equal annual installments beginning one day prior to the date of the first annual meeting of the Issuer's stockholders following the day of grant and continuing for the next two annual meeting of the Issuer's stockholders, such that the option will be fully vested one day prior to the date of the third annual meeting of the Issuer's stockholders following the day of the grant, provided that at the relevant vesting dates such optionee's directorial relationship has not been terminated as defined in and as determined under the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer.